Immune Therapy and Analytical Treatment Interruption in HIV+ Participants Who Received an Allogeneic Stem Cell Transplantation

HIV Infection Clinical Trial

— ITATI  

Official title:

Immune Therapy and Analytical Treatment Interruption in HIV+ Participants Who Received an Allogeneic Stem Cell Transplantation (ITATI)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04720742
• Other study ID #: ITATI
• Status: Withdrawn
• Phase: Phase 2
• Start date: February 28, 2021
• Est. completion date: March 28, 2022

Study information

• Verified date: August 2022
• Source: IrsiCaixa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The availability of antiretroviral therapy (cART) for HIV-1 infection has led to a reduction in morbidity in patients with chronic HIV infection. However, cART does not eliminate HIV-1 that persists as a latent infection in cellular reservoirs. Usually, HIV viremia rapidly rebounds if antiretroviral therapy is interrupted. Consequently, HIV infected individuals must commit to expensive, life-long therapies and must tackle problems associated with chronic infection and uninterrupted cART, including continuous clinical and laboratory monitoring, drug toxicities, and chronic immune activation/inflammation.

Currently, there is an emerging interest in developing safe and affordable curative strategies that would eliminate the need for lifelong therapy. However, to date only allogeneic hematopoietic stem cell transplantation (allo-HSCT) has shown results in decreasing the HIV-1 reservoirs.

The IciStem Consortium (www.icistem.org) has assembled the largest and most exhaustive observational cohort for the study of HIV reservoir dynamics in allo-HSCT HIV+ individuals with severe hematological malignancies worldwide. Within the cohort, only individuals transplanted with a donor with thw CCR5A32 mutation have shown signs of HIV remission. On the other side broadly neutralizing antibodies (bNAbs) have shown the potential to control HIV infection. This study intends to evaluate if the allo-HSCT combined with the additional application of bNAbs is effective to control HIV replication.

Description:

The availability of antiretroviral therapy (cART) for HIV-1 infection has led to a reduction in morbidity in patients with chronic HIV infection. However, cART does not eliminate HIV-1 that persists as a latent infection in cellular reservoirs. Usually, HIV viremia rapidly rebounds if antiretroviral therapy is interrupted. Consequently, HIV infected individuals must commit to expensive, life-long therapies and must tackle problems associated with chronic infection and uninterrupted cART, including continuous clinical and laboratory monitoring, drug toxicities, and chronic immune activation/inflammation.

Currently, there is an emerging interest in developing safe and affordable curative strategies that would eliminate the need for lifelong therapy. However, to date only allogeneic hematopoietic stem cell transplantation (allo-HSCT) has shown results in decreasing the HIV-1 reservoirs.

The IciStem Consortium (www.icistem.org) has assembled the largest and most exhaustive observational cohort for the study of HIV reservoir dynamics in allo-HSCT HIV+ individuals with severe hematological malignancies worldwide. Within the cohort, only individuals transplanted with a donor with thw CCR5A32 mutation have shown signs of HIV remission. On the other side broadly neutralizing antibodies (bNAbs) have shown the potential to control HIV infection. This study intends to evaluate if the allo-HSCT combined with the additional application of bNAbs is effective to control HIV replication.

Detailed Description:

The implementation of highly effective, convenient, and well-tolerated combination antiretroviral therapy (cART) for HIV-1 infection has substantially reduced AIDS-related morbidity and mortality. However, cART does not eliminate HIV-1 that persists as a latent infection in cellular reservoirs, including resting memory CD4+ T cells, leading to an underlying raised state of immune activation and subsequent immune senescence. Of note, HIV viremia rapidly rebounds if antiretroviral therapy is interrupted. Consequently, HIV infected individuals must commit to expensive, life-long therapies and must tackle problems associated with chronic infection and uninterrupted cART, including continuous clinical and laboratory monitoring, drug toxicities, and chronic immune activation/inflammation. Therefore, there is an emerging interest in developing safe and affordable curative strategies that would eliminate the need for lifelong therapy while improving the health of infected subjects and reducing the risk of viral transmission to uninfected individuals. So far, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only intervention to date that systematically reduces HIV-1 reservoirs to undetectable levels regardless of the CCR5Δ32 donor status.

IciStem is a prospective observational project to investigate cases of allo-HSCT in HIV-1-infected individuals and their putative remission. Over the last few years, the IciStem Consortium (www.icistem.org) has assembled the largest and most exhaustive observational cohort for the study of HIV reservoir dynamics in allo-HSCT HIV+ individuals with severe hematological malignancies worldwide. 39 individuals have already been transplanted and followed up in the IciStem cohort and subsequent undetectable HIV reservoirs in blood and tissues have been described in those with 100% chimerism while still on antiretroviral treatment (ART).

Detailed analysis of CCR5wt allo-HSCT cases within the IciStem cohort has provided insights on additional factors such as conditioning regimen, total body irradiation, graft versus host disease, and viral tropism that contribute to eradication of the potentially infectious viral reservoir in addition to the lack of a functional CCR5 receptor. Allo-HSCT has proved a profound effect on the HIV reservoir. So far, only participants with homozygous CCR5Δ32 mutation have shown signs of HIV remission whereas participants without the CCR5Δ32 mutation had a delayed rebound during ATI. bNAbs have shown the potential to control HIV infection. Consequently, the combination of allo-HSCT with these antibodies is one of the aims of the study by which new cases of HIV remission might be achieved in this setting.

During the last 48 months IciStem has generated a prospective observational cohort of 39 cases of allo-HSCT in HIV-positive participants with severe hematological malignancies in 21 clinical sites in 9 countries (Europe and Canada). Those 39 cases (from the 45 registered) have been followed up with continuous sample collection and high-resolution state of the art virological and immunological analysis. A summary of preliminary studies and achievements is listed below

1. Nine transplants involved CCR5Δ32/Δ32 donors, and 18 involved CCR5wt donors.

2. Mean post-HSCT follow-up is 1656 days, with 18 participants alive in active follow-up (4 transplanted with CCRΔ32/Δ32 donor); 13 IciStem participants are beyond the 2nd year post-HSCT, respectively. From those, 8 are out of immune suppression and with minimal-undetectable HIV latent reservoirs.

3. Five participants from the IciStem Cohort are currently suitable to enter in the first ITATI approach within the IciStem core. Those 5 participants have no detectable replication competent HIV reservoir in presence of cART and have been followed up for the longest time.

The therapeutically intervention for these participants will be an analytical treatment interruption with additional application of broadly neutralizing antibodies (bNAbs) that recently have been described as safe and effective to control HIV replication in infected participants. The rationale for application of these bNAbs during the treatment interruption of the IciStem participants:

• To help prevent viral rebound in absence of cART, due to their proven capacity to potently and durably suppress any possible residual HIV replication

• To rapidly eliminate a cell producing virus via mechanisms such as ADCC (Antibody dependent cellular cytotoxicity)

• To facilitate the development of a broad CTL (Cytotoxic T lymphocytes) response sufficient to maintain remission, as demonstrated in macaques/SHIV studies (Nishimura, 2017)

• To protect the individuals from a putative viral rebound with a safe system, as bNAbs application has few side effects and rarely causes adverse events

• To achieve a highly specific targeting and inhibition of HIV to avoid massive overall bystander activation of the immune system that in effect could lead to a higher chance of HIV reinfection of activated CD4+ T cells.

Despite cART has substantially reduced HIV-related morbidity and mortality, HIV reservoirs are still present and represent a key concern currently for HIV remission. This fact has resulted in a chronicity of HIV infection, leading to emotional disturbances and psychological burden associated with this perpetuation of the disease in the daily living. In the setting of HIV eradication trials, analytical interruption of antiretroviral therapy is a requirement to investigate HIV remission, control, and potential viral rebound. However, discontinuation of cART is linked to psychological issues that should be considered in the setting of HIV cure trials:

1. Stopping cART may lead to variable clinical detriments. Those detriments may induce worry and psychological distress, which can not only worsen the quality of life, but also cause an instability of the emotional status. At the same time, that breakdown of the emotional system may influence the clinical status. Even when clinical consequences are not manifested or self-perceived, beliefs about unfavorable health-related results and desperation for HIV remission may arise.

2. Interrupting cART may increase the risk to infect other people. Those who discontinue cART may not be willing therefore to put their sexual partners at risk. Even after deciding to participate and to interrupt cART, they may develop worries and fears about infecting others.

3. This sort of HIV remission trial comprises a very specific collective of people. People who have suffered from a hematologic medical complication indicative for stem cell transplantation and have survived this severe health problem.

This fact already indicates an impacted emotional status (without even considering the ITATI). Besides, specifically in the current study, additional medical strategies will be applied. Those interventions will be new for the participants (i.e., immune therapy) and will require multiple additional medical appointments. Those characteristics add complexity to the psychological management during the participation in the study.

For all the reasons presented, the participants' psychological predisposition to ITATI and the participation in the study and the emotional status will be monitored carefully throughout the trial. This will be managed at 2 levels: first by continuous assessment of the emotional status and second by offering emotional support whenever required, especially considering the cessation of cART and initiation of the immune therapy.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 28, 2022
• Est. primary completion date: March 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• More than 2 years post-HSCT

• Being off immunosuppression for at least one year (related to allo-HSCT)

• Undetectable levels of HIV replication competent reservoirs in blood (< 0,1 IUPM).

• CD4 count levels higher than 200 cel/mm3.

• Aged at least 18 years and not older than 65 at the day of screening

• Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.

• In the opinion of the principal investigator or designee, the participant has understood the information provided and capable of giving written informed consent.

• If heterosexually active female; using an effective method of contraception (hormonal contraception, intra-uterine device (IUD), or anatomical sterility in self or partner1) from 14 days prior to the first bNAbs administration until at least 6 months after the last bNAbs administration; all female volunteers must be willing to undergo urine pregnancy tests at time points specified.

• If heterosexually active male; willing to use an effective method of contraception (anatomical sterility in self) or agree on the use of an effective method of contraception by his partner(hormonal contraception, intra-uterine device (IUD), or anatomical sterility1 from the day of the first bNAbs administration until 6 months after the last bNAbs administration.

• Willing to accept blood draws at time points specified.

• Not sharing injection drug equipment, such as needles.

1. Condom use nor diaphragm are considered as an additional method of contraception only and cannot be the only method of contraception used as not been considered an effective method by the Clinical Trial Facilitation Group (CTFG) guidelines.

Exclusion Criteria:

• Pregnancy or lactating

• Participation in another clinical trial within 12 weeks of study entry (at screening period).

• History or clinical manifestations of any physical or psychiatric disorder which could impair the subject's ability to complete the study.

Related Conditions & MeSH terms

• HIV Infection
• HIV Infections

Intervention

Drug:
• Analytical Treatment Interruption + bNAbs infusion
The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration. During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074

Locations

Country	Name	City	State
Italy	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano	Milan	Lombardy
Netherlands	University Medical Center Utrecht	Utrecht
Spain	Complejo Hospitalario Universitario de Granada	Granada	Andalucia
Spain	Hospital Gregorio Marañón	Madrid

Sponsors (1)

Lead Sponsor	Collaborator
IrsiCaixa

Countries where clinical trial is conducted

Italy,  Netherlands,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Levels of residual HIV-1 RNA and viral proteins in plasma	Levels of residual HIV-1 RNA and viral proteins in plasma before, during and after infusions of 3BNC117 and 10-1074.	Visits from Baseline to 8 months
Other	Levels of cellular HIV-1 RNA	Levels of cellular HIV-1 RNA before, during and after infusions of 3BNC117 and 10-1074	Visits from Baseline to 8 months
Other	Quality of the autologous antibodies.	HIV-1 specific humoral cell immune responses before, during and following 3BNC117 and 10-1074 infusions, including quantity and quality of the autologous antibodies.	Visits from Baseline to 8 months
Other	Quantity of the autologous antibodies.	HIV-1 specific humoral cell immune responses before, during and following 3BNC117 and 10-1074 infusions, including quantity and quality of the autologous antibodies.	Visits from Baseline to 8 months
Other	Immunophenotype and functional characteristics of NK, B and T cells from peripheral blood	Immunophenotype and functional characteristics of NK, B and T cells from peripheral blood before, during and following the 3BNC117 and 10-1074 infusions.	Visits from Baseline to 8 months
Other	Measurement of Immune activation and proliferation markers	Measurement of immune activation and proliferation markers, before, during and following 3BNC117 and 10-1074 infusions.	Visits from Baseline to 8 months
Other	Measurement of plasma biomarkers	Measurement of plasma biomarkers and relate them to HIV viral rebound.	At viral rebound
Other	Genome amplification (SGA), phenotypic characterization and full genome analysis of rebounded viruses	Single genome amplification (SGA), phenotypic characterization and full genome analysis (integration sites and tropism) of rebounded viruses after ART interruption, and after at least 12 weeks after ART re-suppression of viral replication	From Baseline and 12 weeks after viral re-suppression
Other	Immunophenotype and functional characteristics of viral specific T cells	Immunophenotype and functional characteristics of viral specific T cells in the viral rebound.	At viral rebound
Other	Measurement of HIV-1 total reservoir	Measurement of HIV-1 total reservoir (determined by the number of HIV-DNA or HIV-RNA copies using ddPCR) in ileum, bone marrow, lymph node and CSF biopsies after 18 months of treatment interruption without viral rebound.	At 18 months without viral rebound
Other	Evaluation of the HIV latent reservoirs in blood	Evaluation of the HIV latent reservoirs in blood by infusion of the participant's CD4+ T cells in a mice model after 18 months of treatment interruption without viral rebound.	At 18 months without viral rebound
Other	Measurement of ultra-chimerism in blood and tissue populations	Measurement of ultra-chimerism in blood and tissue populations before, during and after the 3BNC117 and 10-1074 infusions	Visits from Baseline to 8 months
Other	Analysis of metabolic products of glycolysis in plasma	Analysis of metabolic products of glycolysis in plasma before, during and after the 3BNC117 and 10-1074 infusions.	Visits from Baseline to 8 months
Other	Change in the scores assessing psychological predisposition to Analytical Treatment Interruption (ATI) and emotional status	Evaluation of significant change in the scores assessing psychological predisposition to Analytical Treatment Interruption (ATI) and emotional status.	At Screening, Baseline, 1 month, 8 months, 9 months, 12 months, 18 months and 3 months after viral suppression
Other	Quantification of the satisfaction level	Quantification of the satisfaction levels of the participation in the study.	At 8 months, 18 months and 3 months after viral suppression
Primary	Time to reappearance of HIV-1 viremia	Time to reappearance of HIV-1 viremia (plasma HIV-1 RNA level > 50 copies/ml in 2 consecutive measurements) after ART interruption.	From Baseline to 18 months
Primary	Time to reappearance of HIV-1 replication competent reservoir	Time to reappearance of HIV-1 replication competent reservoir (determined by the number of infectious units per 106 CD4+ T cells (IUPM) using a viral outgrowth assay) after ART interruption.	From Baseline to 18 months
Primary	Time to reappearance of HIV-1 total reservoir	Time to reappearance of HIV-1 total reservoir (determined by the number HIV-DNA copies per 106 CD4+ T cells using ddPCR) after ART interruption.	From Baseline to 18 months
Secondary	Rate and severity of adverse events (AE) and serious adverse events (SAE)	Safety evaluation, as measured by rate and severity of adverse events (AE) and serious adverse events (SAE).	From Baseline to 18 months
Secondary	Serum levels of 3BNC117 and 10-1074	Serum levels of 3BNC117 and 10-1074 throughout the study	From Baseline to 18 months